<ѻý>Neuromuscular Training Decreased Incidence of Chemo-Induced Peripheral Neuropathyѻý> Incidence significantly reduced with two types of exercises versus usual care Jul 01, 2024
<ѻý>Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trialsѻý> News, features, and commentary about cancer-related issues Jun 28, 2024
<ѻý>Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteriaѻý> No difference in adverse events, clinical benefit, OS for patients with or without waivers Jun 27, 2024
<ѻý>Young Cervical Cancer, Leukemia Survivors at Greater Risk of Obstetric Complicationsѻý> Population-based study suggests reassurance for most, high-risk strategies for some Jun 27, 2024
<ѻý>CAR T-Cell Therapy in Functional High-Risk Multiple Myelomaѻý> Joseph Mikhael, MD, leads a discussion on the subgroup analysis of CARTITUDE-4 Jun 27, 2024 video
<ѻý>What's a Normal PSA Value for Transgender Women on Estrogen Therapy?ѻý> Study suggests threshold is too high to identify risk of prostate cancer in this population Jun 26, 2024
<ѻý>Oncology Drug Shortages Persist, but Continue to Evolveѻý> Supply-chain issues, unrealistically low prices for generics, hoarding, other factors to blame Jun 26, 2024
<ѻý>Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancerѻý> Adding the mTOR inhibitor didn't improve EFS in intermediate-risk rhabdomyosarcoma Jun 25, 2024
<ѻý>Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injuryѻý> Case reports may not be as reliable, researchers say Jun 25, 2024
<ѻý>Combo of Approved Agents Active in High-Risk Large B-Cell Lymphomaѻý> Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients Jun 25, 2024 video
<ѻý>Acupuncture Reduced Hot Flashes Related to Endocrine Therapy for Breast Cancerѻý> 64% of women reported at least a 50% reduction in hot flash frequency and severity Jun 24, 2024
<ѻý>Subcutaneous C5 Inhibitor Approved for PNHѻý> Longer-acting crovalimab designed for more sustained effect and less treatment burden Jun 24, 2024
<ѻý>Treating Advanced Breast Cancer After Progression on CDK4/6 Inhibitorsѻý> Results from postMONARCH offer one path Jun 24, 2024 video
<ѻý>Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverageѻý> Not all preventive care recommended by the USPSTF is threatened by the narrow ruling, however Jun 24, 2024
<ѻý>Adagrasib Wins Accelerated Approval for KRAS-Mutant Colorectal Cancerѻý> KRAS inhibitor plus cetuximab achieved 34% response rate, 85% disease control in early trial Jun 21, 2024
<ѻý>ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancerѻý> Clinical landscape has shifted away from traditional risks for H&N cancer to HPV predominance Jun 21, 2024
<ѻý>ALK Inhibitor Shows Promise in Rare, Progressive Tumor Typesѻý> Phase II study found brigatinib exceeded historical control by shrinking 10% of targeted tumors Jun 21, 2024
<ѻý>EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancerѻý> News, features, and commentary about cancer-related issues Jun 21, 2024
<ѻý>Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLCѻý> No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response Jun 20, 2024
<ѻý>Glofitamab Regimen Improves Survival in DLBCLѻý> Granted accelerated approval last year, bispecific antibody passes its confirmatory test Jun 20, 2024
<ѻý>Using MRD Status to Deescalate Multiple Myeloma Therapyѻý> Joseph Mikhael, MD, leads a discussion on the findings of the MRD2STOP study Jun 20, 2024 video
<ѻý>Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCLѻý> High-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line Jun 19, 2024
<ѻý>Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopeniaѻý> "Rapid and sustained" efficacy in 95% of pretreated patients in small trial Jun 19, 2024
<ѻý>Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLLѻý> Undetectable MRD rates of 90% or higher, PFS of 7 years or more Jun 17, 2024
<ѻý>Two New Immunotherapy-Chemo Options Approved for Endometrial Cancerѻý> New indications for pembrolizumab and durvalumab in advanced disease Jun 17, 2024
<ѻý>New Standard of Care in High-Risk Acute Promyelocytic Leukemia?ѻý> All-trans retinoic acid plus arsenic trioxide and idarubicin improved EFS over standard Jun 17, 2024
<ѻý>I Tried to Protect My Mother From Dying in Pain. The Law Robbed Her of That Dignity.ѻý> It's time to clear the roadblocks to Medical Aid in Dying in the U.S. Jun 16, 2024
<ѻý>Train Eyes So Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Strokeѻý> Also in TTHealthWatch: cancers subsequent to CAR-T therapy Jun 15, 2024 podcast
<ѻý>Atezolizumab Consolidation Impresses in High-Risk DLBCLѻý> Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation? Jun 14, 2024
<ѻý>Kate Middleton Gives Cancer Updateѻý> Princess of Wales says she's making "good progress" in treatment Jun 14, 2024
<ѻý>Adding Isatuximab to Standard Backbone Prolongs PFS in Myelomaѻý> Joseph Mikhael, MD, leads a roundtable discussion on two positive phase III trials from ASCO Jun 14, 2024 video
<ѻý>Early Menopause Tied to Higher Risk of Respiratory Mortalityѻý> Greatest risk observed for women with bilateral oophorectomy Jun 13, 2024
<ѻý>Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?ѻý> News, features, and commentary about cancer-related issues Jun 13, 2024
<ѻý>AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancerѻý> AI detected 6.8% more clinically significant cancers, 20% fewer indolent cancers Jun 13, 2024
<ѻý>Tanning Salons Are Overdue for a Regulatory Burnѻý> In the meantime, don't forget to educate patients on the risks Jun 13, 2024
<ѻý>New Clues to Origin of T-Cell Lymphoma After CAR-T Therapyѻý> Co-mutations, viral link, potential common susceptibility emerge from two studies Jun 12, 2024
<ѻý>Brigatinib Makes Its Case for ALK-Positive ALCL in Small Studyѻý> Second-gen ALK inhibitor induces high response rate, associated with impressive survival Jun 12, 2024
<ѻý>Nanoliposomal Irinotecan Fails to Boost Survival in Treated Advanced Biliary Cancerѻý> No difference in PFS, median OS favored control group Jun 12, 2024
<ѻý>Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancerѻý> Half of patients responded, but editorialists call for new directions in therapy development Jun 11, 2024
<ѻý>Middle-Age Man Presents With Necrotizing Mass on Noseѻý> Rare condition can be deadly without early diagnosis and treatment Jun 10, 2024